Table 2.

Analysis to evaluate the influence of age and dose on the effect of RV in T2DM.

Subgroup	No. of Trials	Effect Size	95% CI	p-Value	Heterogeneity (I2)	p-Value for I2
Glucose −14.13 (−20.90,−7.36) p < 0.0001
RV dosage (I2 = 58%; p = 0.07)
<250 mg/day	4	−5.41	−12.74, 1.93	0.15	42%	0.16
250–500 mg/day	5	−20.72	−30.62, −10.83	<0.0001	90%	<0.00001
>500–1000 mg/day	5	−16.40	−34.05, 1.25	0.07	91%	<0.00001
>1000 mg/day	1	3.60	−24.87, 32.07	0.80	----	----
Age (I2 = 84%; p = 0.01)
45–59 years	12	−17.73	−25.93, −9.54	<0.0001	95%	<0.00001
≥60 years	3	−2.00	−11.29, 7.28	0.67	64%	0.06
HbA1c −0.27 (−0.44, −0.10) p = 0.002
RV dosage (I2 = 78%; p = 0.003)
<250 mg/day	4	−0.04	−0.27, 0.19	0.72	77%	0.005
250–500 mg/day	3	−0.58	−0.76, −0.39	<0.0001	98%	0.00001
>500–1000 mg/day	4	−0.26	−0.71, 0.19	0.25	81%	0.001
>1000 mg/day	1	−0.90	−2.00, 0.20	0.11	----	----
Age (I2 = 95%; p = 0.0001)
45–59 years	10	−0.37	−0.54, −0.20	<0.0001	96%	0.0001
≥60 years	2	0.17	0.01, 0.34	0.04	0%	0.62
Insulin −1.36 (−2.03, −0.68) p < 0.0001
RV dosage (I2 = 0; %; p = 0.92)
<250 mg/day	4	−1.22	−1.73, −0.71	<0.0001	0%	0.56
250–500 mg/day	3	−1.55	−3.08, −0.03	0.05	81%	0.00
>500–1000 mg/day	3	−1.99	−5.19, 1.21	0.22	80%	0.006
>1000 mg/day	1	−0.40	−4.97, 4.17	0.86	----	----
Age (I2 = 0%; p = 0.92)
45–59 years	9	−1.39	−2.21, −0.56	0.001	73%	0.0003
≥60 years	2	−1.32	−2.23, −0.41	0.005	69%	<0.0001
HOMA-IR −0.77 (−1.60, 0.06) p = 0.07
RV dosage (I2 = 26%; p = 0.26)
<250 mg/day	3	−0.41	−1.10, 0.29	0.25	63%	0.07
250–500 mg/day	3	−1.08	−2.16, 0.01	0.05	92%	0.00001
>500–1000 mg/day	4	−1.06	−2.95, 0.83	0.27	97%	0.00001
>1000 mg/day	1	0.31	−0.65, 1.26	0.53	----	----
Age (I2 = 0%; p = 0.41)
45–59 years	9	−0.84	−1.83, 0.15	0.10	96%	0.00001
≥60 years	2	−0.40	−0.70, −0.11	0.007	0%	0.89

Abbreviations: CI, confidence interval; HbA1c, glycated hemoglobin; HOMA-IR, insulin resistance (homeostatic model); RV, resveratrol.